These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28609797)

  • 1. Response to: "More on the Limitations of the aPTT for Monitoring Argatroban Therapy".
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Sep; 43(6):644. PubMed ID: 28609797
    [No Abstract]   [Full Text] [Related]  

  • 2. More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy.
    Guy S; Van Veen J; Kitchen S
    Semin Thromb Hemost; 2017 Sep; 43(6):642-643. PubMed ID: 28618436
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
    John TE; Hallisey RK
    Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
    Pendleton R; Wheeler MM; Rodgers GM
    Ann Pharmacother; 2006 May; 40(5):972-6. PubMed ID: 16569813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
    Guy S; Kitchen S; Maclean R; Van Veen JJ
    Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
    Shapiro NL; Durr EA; Krueger CD
    Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
    Hursting MJ; Verme-Gibboney CN
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
    Smythe MA; Koerber JM; Forsyth LL; Priziola JL; Balasubramaniam M; Mattson JC
    Pharmacotherapy; 2009 Sep; 29(9):1073-81. PubMed ID: 19698012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case series describing the use of argatroban in patients on extracorporeal circulation.
    Cornell T; Wyrick P; Fleming G; Pasko D; Han Y; Custer J; Haft J; Annich G
    ASAIO J; 2007; 53(4):460-3. PubMed ID: 17667231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban anticoagulation in critically ill patients.
    Beiderlinden M; Treschan TA; Görlinger K; Peters J
    Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombelastography in a patient with heparin-induced thrombocytopenia treated with argatroban.
    Zayac EA; Pivalizza EG; Levine RL
    Anesth Analg; 2008 Jan; 106(1):351-2. PubMed ID: 18165611
    [No Abstract]   [Full Text] [Related]  

  • 19. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial.
    Tardy-Poncet B; Nguyen P; Thiranos JC; Morange PE; Biron-Andréani C; Gruel Y; Morel J; Wynckel A; Grunebaum L; Villacorta-Torres J; Grosjean S; de Maistre E
    Crit Care; 2015 Nov; 19():396. PubMed ID: 26556106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.